Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Deutsches Herzzentrum Muenchen Technische Universität München |
---|---|
Information provided by: | Deutsches Herzzentrum Muenchen |
ClinicalTrials.gov Identifier: | NCT00598715 |
For lesions which develop restenosis after a DES, it is not known which the right strategy to use is, implantation of the same type of DES as the initial one or a DES with a different drug.
Condition | Intervention | Phase |
---|---|---|
Coronary Artery Disease |
Device: Sirolimus eluting stent (Cypher) Device: Paclitaxel-eluting stent |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Prospective, Randomized Trial of Paclitaxel- vs Sirolimus-Eluting Stents for Treatment of Coronary Restenosis in Sirolimus-Eluting Stents |
Estimated Enrollment: | 360 |
Study Start Date: | October 2007 |
Estimated Study Completion Date: | June 2009 |
Estimated Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
due to randomisation patients will get a Sirolimus eluting stent
|
Device: Sirolimus eluting stent (Cypher)
Sirolimus eluting stent will be implanted
|
2: Experimental
due to randomisation patients will get a Paclitaxel eluting stent
|
Device: Paclitaxel-eluting stent
Paclitaxel eluting stent will be implanted (Taxus)
|
Treatment of in-stent restenosis after implantation of a DES has poorly been studied. Although there are no data, it may be assumed that certain lesions might be resistant to a given drug and in need of a different DES. Thus, for lesions which develop restenosis after a DES, it is not known which the right strategy to use is, implantation of the same type of DES as the initial one or a DES with a different drug. This prospective, randomized trial will compare the anti-restenotic efficacy of PES or SES in patients with restenosis after initial implantation of a SES
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Julinda Mehilli, MD | +49 89 1218 ext 4582 | mehilli@dhm.mhn.de |
Contact: Stefanie Schulz, MD | +49 89 1218 ext 1534 | schulzs@dhm.mhn.de |
Germany | |
Deutsches Herzzentrum Muenchen | Recruiting |
Munich, Germany, 80636 | |
Contact: Mehilli |
Principal Investigator: | Kastrati | Deutsches Herzzentrum Muenchen |
Responsible Party: | Deutsches Herzzentrum Muenchen ( Prof. A. Schömig ) |
Study ID Numbers: | GE IDE No. S02407 |
Study First Received: | January 10, 2008 |
Last Updated: | January 28, 2009 |
ClinicalTrials.gov Identifier: | NCT00598715 History of Changes |
Health Authority: | Germany: German Institute of Medical Documentation and Information |
In-stent restenosis |
Arterial Occlusive Diseases Sirolimus Heart Diseases Immunologic Factors Clotrimazole Miconazole Myocardial Ischemia Tioconazole Vascular Diseases Antimitotic Agents Ischemia |
Arteriosclerosis Immunosuppressive Agents Coronary Restenosis Coronary Disease Anti-Bacterial Agents Paclitaxel Antifungal Agents Tubulin Modulators Antineoplastic Agents, Phytogenic Coronary Artery Disease |
Sirolimus Anti-Infective Agents Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myocardial Ischemia Physiological Effects of Drugs Arteriosclerosis Antibiotics, Antineoplastic Anti-Bacterial Agents Therapeutic Uses Antifungal Agents Cardiovascular Diseases |
Arterial Occlusive Diseases Heart Diseases Mitosis Modulators Vascular Diseases Antimitotic Agents Immunosuppressive Agents Pharmacologic Actions Coronary Disease Paclitaxel Tubulin Modulators Antineoplastic Agents, Phytogenic Coronary Artery Disease |